Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters

[1]  Dorte Nielsen,et al.  Triple negative breast cancer – prognostic role of immune-related factors: a systematic review , 2018, Acta oncologica.

[2]  M. Duffy,et al.  Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). , 2017, European journal of cancer.

[3]  Yul Ri Chung,et al.  Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status , 2017, Breast Cancer Research and Treatment.

[4]  Tao Zhang,et al.  Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis , 2016, Oncotarget.

[5]  O. Gluz,et al.  The prognostic impact of age in different molecular subtypes of breast cancer , 2015, Breast Cancer Research and Treatment.

[6]  S. Leung,et al.  Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration , 2014, Breast Cancer Research.

[7]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[8]  D. McMillan,et al.  The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. , 2012, Cancer treatment reviews.

[9]  W. Foulkes,et al.  Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade , 2011, Histopathology.

[10]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.